Delivery Order SPE2DB20D3303-SPE2DB26FY2E1
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,043.61 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of October 24, 2025. This firm fixed-price delivery order, awarded on October 23, 2025, with no set-aside designation, represents a competitively awarded transaction for pharmaceutical supply to support federal medical procurement needs. The place of performance is AmerisourceBergen's corporate office...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,061.39 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract, awarded on October 27, 2025, represents a firm fixed-price delivery order with an ultimate completion date of October 28, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. This non-set-aside award was competitively awarded to AmerisourceBergen, a major pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/ml SureClick auto-injectors, with a contract ceiling value of $2,270.22. The award was made on August 21, 2025, with an ultimate completion date of August 22, 2025. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency has awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, valued at $10,380.32 under a firm fixed price contract. The award was issued on August 6, 2025, with an ultimate completion date of August 7, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order carries no set-aside designation and was competitively awarded through the federal...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $34,507.05 to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of September 3, 2025. This competitively awarded, firm fixed-price delivery order was issued under a non-set-aside procurement and represents a single transaction for pharmaceutical supply to support federal medical needs. The place of performance is AmerisourceBergen's corporate office in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a $11,796.04 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of October 27, 2025. This is a firm fixed price delivery order with no set-aside designation, issued competitively to the pharmaceutical distributor's Conshohocken, Pennsylvania facility. The award represents a discrete delivery under AmerisourceBergen's broader contract portfolio supporting federal medical...
- The Defense Logistics Agency awarded a $5,141.32 delivery order (Contract No. 4569811046) to AmerisourceBergen Drug Corp for Repatha 140 mg/mL SureClick auto-injectors, with an ultimate completion date of October 24, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The product will be delivered to AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency awarded a delivery order valued at $6,948.71 to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of November 5, 2025. This non-competitive, firm fixed-price delivery order was issued on November 4, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA's Medical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,480.40 to AmerisourceBergen Drug Corp for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract was competitively awarded without set-aside designation and carries an ultimate completion date of July 29, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends...
- The Defense Logistics Agency (DLA) awarded a $8,634.89 delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors, with an ultimate completion date of October 31, 2025. This firm fixed-price delivery order, issued on October 30, 2025, supports the federal government's pharmaceutical supply needs through a competitive procurement process with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate headquarters location in...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB26FY2E1Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Repatha 140 mg/ml SureClick auto-injectors valued at $8,930.27 under a firm fixed-price contract type. This delivery order, issued on November 5, 2025, with an ultimate completion date of November 6, 2025, represents a non-competitive award under DLA's existing pharmaceutical supply framework. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, which serves as a primary distribution hub for federal medical procurement. This delivery order is a child contract executed under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement running through December 2026. The IDC provides comprehensive global pharmaceutical support to military healthcare systems and enables the company to supply a wide range of medications, vaccines, medical devices, and specialized healthcare commodities. Repatha, a cardiovascular medication used for managing cholesterol levels, aligns with AmerisourceBergen's extensive portfolio of specialty pharmaceuticals and medical supplies supporting Defense Health Agency requirements and other federal healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.9k | 11/5/25 |